PURPOSE: Wilms tumor is the most common renal neoplasm of childhood. We previously found that restricted activation of the WNT/β-catenin pathway in renal epithelium late in kidney development is sufficient to induce small primitive neoplasms with features of epithelial Wilms tumor. Metastatic disease progression required simultaneous addition of an activating mutation of the oncogene K-RAS. We sought to define the molecular pathways activated in this process and their relationship to human renal malignancies. MATERIALS AND METHODS: Affymetrix® expression microarray data from murine kidneys with activation of K-ras and/or Ctnnb1 (β-catenin) restricted to renal epithelium were analyzed and compared to publicly available expression data on normal and neoplastic human renal tissue. Target genes were verified by immunoblot and immunohistochemistry. RESULTS: Mouse kidney tumors with activation of K-ras and Ctnnb1, and human renal malignancies had similar mRNA expression signatures and were associated with activation of networks centered on β-catenin and TP53. Up-regulation of WNT/β-catenin targets (MYC, Survivin, FOXA2, Axin2 and Cyclin D1) was confirmed by immunoblot. K-RAS/β-catenin murine kidney tumors were more similar to human Wilms tumor than to other renal malignancies and demonstrated activation of a TP53 dependent network of genes, including the transcription factor E2F1. Up-regulation of E2F1 was confirmed in murine and human Wilms tumor samples. CONCLUSIONS: Simultaneous activation of K-RAS and β-catenin in embryonic renal epithelium leads to neoplasms similar to human Wilms tumor and associated with activation of TP53 and up-regulation of E2F1. Further studies are warranted to evaluate the role of TP53 and E2F1 in human Wilms tumor.
PURPOSE:Wilms tumor is the most common renal neoplasm of childhood. We previously found that restricted activation of the WNT/β-catenin pathway in renal epithelium late in kidney development is sufficient to induce small primitive neoplasms with features of epithelial Wilms tumor. Metastatic disease progression required simultaneous addition of an activating mutation of the oncogene K-RAS. We sought to define the molecular pathways activated in this process and their relationship to humanrenal malignancies. MATERIALS AND METHODS: Affymetrix® expression microarray data from murine kidneys with activation of K-ras and/or Ctnnb1 (β-catenin) restricted to renal epithelium were analyzed and compared to publicly available expression data on normal and neoplastic human renal tissue. Target genes were verified by immunoblot and immunohistochemistry. RESULTS:Mousekidney tumors with activation of K-ras and Ctnnb1, and humanrenal malignancies had similar mRNA expression signatures and were associated with activation of networks centered on β-catenin and TP53. Up-regulation of WNT/β-catenin targets (MYC, Survivin, FOXA2, Axin2 and Cyclin D1) was confirmed by immunoblot. K-RAS/β-catenin murinekidney tumors were more similar to humanWilms tumor than to other renal malignancies and demonstrated activation of a TP53 dependent network of genes, including the transcription factor E2F1. Up-regulation of E2F1 was confirmed in murine and humanWilms tumor samples. CONCLUSIONS: Simultaneous activation of K-RAS and β-catenin in embryonic renal epithelium leads to neoplasms similar to humanWilms tumor and associated with activation of TP53 and up-regulation of E2F1. Further studies are warranted to evaluate the role of TP53 and E2F1 in humanWilms tumor.
Authors: E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson Journal: Genes Dev Date: 2001-12-15 Impact factor: 11.361
Authors: Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: Maria V Abramova; Evgeny A Zatulovskiy; Svetlana B Svetlikova; Alexander N Kukushkin; Valery A Pospelov Journal: Biochem Biophys Res Commun Date: 2009-11-11 Impact factor: 3.575
Authors: Laura-Maria Krabbe; Mary E Westerman; Aditya Bagrodia; Bishoy A Gayed; Oussama M Darwish; Ahmed Q Haddad; Dina Khalil; Payal Kapur; Arthur I Sagalowsky; Yair Lotan; Vitaly Margulis Journal: J Urol Date: 2013-11-26 Impact factor: 7.450
Authors: Hannah M Phelps; Janene M Pierce; Andrew J Murphy; Hernan Correa; Jun Qian; Pierre P Massion; Harold N Lovvorn Journal: J Pediatr Surg Date: 2019-02-28 Impact factor: 2.545
Authors: Harold N Lovvorn; Janene Pierce; Jaime Libes; Bingshan Li; Qiang Wei; Hernan Correa; Julia Gouffon; Peter E Clark; Jason R Axt; Erik Hansen; Mark Newton; James A O'Neill Journal: Genes Chromosomes Cancer Date: 2015-08-14 Impact factor: 5.006
Authors: Dina Polosukhina; Harold D Love; Hernan Correa; Zengliu Su; Kimberly B Dahlman; William Pao; Harold L Moses; Carlos L Arteaga; Harold N Lovvorn; Roy Zent; Peter E Clark Journal: Mol Oncol Date: 2017-03-15 Impact factor: 6.603
Authors: Balawant Kumar; Rizwan Ahmad; Giovanna A Giannico; Roy Zent; Geoffrey A Talmon; Raymond C Harris; Peter E Clark; Vinata Lokeshwar; Punita Dhawan; Amar B Singh Journal: J Exp Clin Cancer Res Date: 2021-02-23